Identification of TFR2 as a novel ferroptosis‑related gene that serves an important role in prognosis and progression of triple‑negative breast cancer

Yang,Yan; Du,Jie; Huang,Yun-Fei; He,Wei; Liu,Li; Li,Dan; Chen,Rui

doi:10.3892/ol.2023.14176

Identification of TFR2 as a novel ferroptosis‑related gene that serves an important role in prognosis and progression of triple‑negative breast cancer

Authors:
- Yan Yang
- Jie Du
- Yun-Fei Huang
- Wei He
- Li Liu
- Dan Li
- Rui Chen
View Affiliations

Affiliations: Department of Laboratory Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003, P.R. China, School of Laboratory Medicine, Zunyi Medical University, Zunyi, Guizhou 563003, P.R. China, Clinical Medical College, Zunyi Medical University, Zunyi, Guizhou 563003, P.R. China, Department of General Surgery, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou 563003, P.R. China
Published online on: December 5, 2023 https://doi.org/10.3892/ol.2023.14176
Article Number: 43
Copyright: © Yang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Effective targeted therapeutic strategies for triple‑negative breast cancer (TNBC), the most malignant subtype of breast cancer, are currently lacking. Ferroptosis has been reported to be associated with the onset and advancement of various cancer types, including TNBC. However, there are limited studies on the correlation between TNBC and ferroptosis‑related genes. In addition, the potential biomarkers of ferroptosis in TNBC need further investigation. The present study aimed to assess the prognostic role of a novel ferroptosis‑related gene signature in the context of TNBC. The signature was established utilizing The Cancer Genome Atlas dataset. This three‑gene model [transferrin receptor 2 (TFR2), regulator of G protein signaling 4 and zinc finger protein 36] was developed utilizing least absolute shrinkage and selection operator regression analysis and demonstrated satisfactory predictive performance in TNBC. The area under the curve values of the receiver operating characteristic curves in this model concerning the 1‑, 2‑ and 3‑year survival prediction were 0.721, 0.840 and 0.856, respectively. The predictive performance of the model was verified using the TNBC dataset GSE25307. Gene set enrichment analysis (GSEA) demonstrated the enrichment of genes in the low‑risk group in a number of important metabolic pathways. Single‑sample GSEA demonstrated a variation in the expression levels of immune checkpoint molecules between the high‑ and low‑risk groups. The inhibitory impact of TFR2 knockdown on the proliferative capacity of TNBC cells was verified through in vitro experiments. The data also demonstrated that TFR2 knockdown facilitated the ferroptosis of TNBC cells. Additional assessments indicated that the effects of TFR2 knockdown were partially reversed upon treatment with the ferroptosis inhibitor ferrostatin‑1. In conclusion, in the present study, a novel and accurate ferroptosis‑related predictive signature was established for TNBC with potential future clinical applications. To the best of our knowledge, the present study is the first to report that TFR2 regulated ferroptosis in TNBC cells in vitro.

View Figures

View References

1	Siegel RL, Miller KD, Fuchs HE and Jemal A: Cancer statistics, 2022. CA Cancer J Clin. 72:7–33. 2022. View Article : Google Scholar : PubMed/NCBI
2	Waks AG and Winer EP: Breast cancer treatment: A review. JAMA. 321:288–300. 2019. View Article : Google Scholar : PubMed/NCBI
3	Sharma M, Turaga RC, Yuan Y, Satyanarayana G, Mishra F, Bian Z, Liu W, Sun L, Yang J and Liu ZR: Simultaneously targeting cancer-associated fibroblasts and angiogenic vessel as a treatment for TNBC. J Exp Med. 218:e202007122021. View Article : Google Scholar : PubMed/NCBI
4	Marra A, Viale G and Curigliano G: Recent advances in triple negative breast cancer: The immunotherapy era. BMC Med. 17:902019. View Article : Google Scholar : PubMed/NCBI
5	Yu B, Luo F, Sun B, Liu W, Shi Q, Cheng SY, Chen C, Chen G, Li Y and Feng H: KAT6A Acetylation of SMAD3 regulates Myeloid-derived suppressor cell recruitment, metastasis, and immunotherapy in Triple-Negative breast cancer. Adv Sci (Weinh). 8:e21000142021. View Article : Google Scholar : PubMed/NCBI
6	Gao W, Wang X, Zhou Y, Wang X and Yu Y: Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy. Signal Transduct Target Ther. 7:1962022. View Article : Google Scholar : PubMed/NCBI
7	Yao Y, Shi Y, Gao Z, Sun Y, Yao F and Ma L: Ferroptosis at the crossroads of tumor-host interactions, metastasis, and therapy response. Am J Physiol Cell Physiol. 323:C95–C103. 2022. View Article : Google Scholar : PubMed/NCBI
8	Sui S, Xu S and Pang D: Emerging role of ferroptosis in breast cancer: New dawn for overcoming tumor progression. Pharmacol Ther. 232:1079922022. View Article : Google Scholar : PubMed/NCBI
9	Singh T, Beatty A and Peterson JR: The AMPK-related kinase NUAK2 suppresses glutathione peroxidase 4 expression and promotes ferroptotic cell death in breast cancer cells. Cell Death Discov. 8:2532022. View Article : Google Scholar : PubMed/NCBI
10	Sha R, Xu Y, Yuan C, Sheng X, Wu Z, Peng J, Wang Y, Lin Y, Zhou L, Xu S, et al: Predictive and prognostic impact of ferroptosis-related genes ACSL4 and GPX4 on breast cancer treated with neoadjuvant chemotherapy. EBioMedicine. 71:1035602021. View Article : Google Scholar : PubMed/NCBI
11	Xu G, Wang H, Li X, Huang R and Luo L: Recent progress on targeting ferroptosis for cancer therapy. Biochem Pharmacol. 190:1145842021. View Article : Google Scholar : PubMed/NCBI
12	Doll S, Proneth B, Tyurina YY, Panzilius E, Kobayashi S, Ingold I, Irmler M, Beckers J, Aichler M, Walch A, et al: ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition. Nat Chemical Biol. 13:91–98. 2017. View Article : Google Scholar
13	Timmerman LA, Holton T, Yuneva M, Louie RJ, Padró M, Daemen A, Hu M, Chan DA, Ethier SP, van't Veer LJ, et al: Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target. Cancer Cell. 24:450–465. 2013. View Article : Google Scholar : PubMed/NCBI
14	Chen PH, Wu J, Ding CC, Lin CC, Pan S, Bossa N, Xu Y, Yang WH, Mathey-Prevot B and Chi JT: Kinome screen of ferroptosis reveals a novel role of ATM in regulating iron metabolism. Cell Death Differ. 27:1008–1022. 2020. View Article : Google Scholar : PubMed/NCBI
15	Tang X, Ding CK, Wu J, Sjol J, Wardell S, Spasojevic I, George D, McDonnell DP, Hsu DS, Chang JT and Chi JT: Cystine addiction of triple-negative breast cancer associated with EMT augmented death signaling. Oncogene. 36:43792017. View Article : Google Scholar : PubMed/NCBI
16	Zhu L, Tian Q, Jiang S, Gao H, Yu S, Zhou Y, Yan Y, Ren Y, He J and Wang B: A novel Ferroptosis-Related gene signature for overall survival prediction in patients with breast cancer. Front Cell Dev Biol. 9:6701842021. View Article : Google Scholar : PubMed/NCBI
17	Győrffy B: Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. Comput Struct Biotechnol J. 19:4101–4109. 2021. View Article : Google Scholar : PubMed/NCBI
18	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
19	Xie Y, Wolff DW, Wei T, Wang B, Deng C, Kirui JK, Jiang H, Qin J, Abel PW and Tu Y: Breast cancer migration and invasion depend on proteasome degradation of regulator of G-protein signaling 4. Cancer Res. 69:5743–5751. 2009. View Article : Google Scholar : PubMed/NCBI
20	Pan QH, Fan YH, Wang YZ, Li DM, Hu CE and Li RX: Long noncoding RNA NNT-AS1 functions as an oncogene in breast cancer via repressing ZFP36 expression. J Biol Regul Homeost Agents. 34:795–805. 2020.PubMed/NCBI
21	Li D, Zhang J and Zhao X: Mechanisms and molecular targets of artemisinin in cancer treatment. Cancer Invest. 39:675–684. 2021. View Article : Google Scholar : PubMed/NCBI
22	Peng Y, Yu H, Zhang Y, Qu F, Tang Z, Qu C, Tian J, Zong B, Wang Y, Ren H and Liu S: A ferroptosis-associated gene signature for the prediction of prognosis and therapeutic response in luminal-type breast carcinoma. Sci Rep. 11:176102021. View Article : Google Scholar : PubMed/NCBI
23	Al-Taie Z, Hannink M, Mitchem J, Papageorgiou C and Shyu CR: Drug repositioning and subgroup discovery for precision medicine implementation in triple negative breast cancer. Cancers (Basel). 13:62782021. View Article : Google Scholar : PubMed/NCBI
24	Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, et al: Ferroptosis: An Iron-dependent form of nonapoptotic cell death. Cell. 149:1060–1072. 2012. View Article : Google Scholar : PubMed/NCBI
25	Liao M, Qin R, Huang W, Zhu HP, Peng F, Han B and Liu B: Targeting regulated cell death (RCD) with small-molecule compounds in triple-negative breast cancer: A revisited perspective from molecular mechanisms to targeted therapies. J Hematol Oncol. 15:442022. View Article : Google Scholar : PubMed/NCBI
26	Wen Y, Chen H, Zhang L, Wu M, Zhang F, Yang D, Shen J and Chen J: Glycyrrhetinic acid induces oxidative/nitrative stress and drives ferroptosis through activating NADPH oxidases and iNOS, and depriving glutathione in Triple-Negative breast cancer cells. Free Radic Biol Med. 173:41–51. 2021. View Article : Google Scholar : PubMed/NCBI
27	Oliveira LJC, Amorim LC, Megid TBC, de Resende CAA and Mano MS: Gene expression signatures in early breast cancer: Better together with clinicopathological features. Crit Rev Oncol Hematol. 175:1037082022. View Article : Google Scholar : PubMed/NCBI
28	Wu ZH, Tang Y, Yu H and Li HD: The role of ferroptosis in breast cancer patients: A comprehensive analysis. Cell Death Discov. 7:932021. View Article : Google Scholar : PubMed/NCBI
29	Tang W, Xu F, Zhao M and Zhang S: Ferroptosis regulators, especially SQLE, play an important role in prognosis, progression and immune environment of breast cancer. BMC Cancer. 21:11602021. View Article : Google Scholar : PubMed/NCBI
30	Stockwell BR: Ferroptosis turns 10: Emerging mechanisms, physiological functions, and therapeutic applications. Cell. 185:2401–2421. 2022. View Article : Google Scholar : PubMed/NCBI
31	Guda MR, Velpula KK, Asuthkar S, Cain CP and Tsung AJ: Targeting RGS4 Ablates Glioblastoma proliferation. Int J Mol Sci. 21:33002020. View Article : Google Scholar : PubMed/NCBI
32	Hu Y, Zheng M, Wang S, Gao L, Gou R, Liu O, Dong H, Li X and Lin B: Identification of a five-gene signature of the RGS gene family with prognostic value in ovarian cancer. Genomics. 113:2134–2144. 2021. View Article : Google Scholar : PubMed/NCBI
33	Park HJ, Kim SH and Moon DO: Growth inhibition of human breast carcinoma cells by overexpression of regulator of G-protein signaling 4. Oncol Lett. 13:4357–4363. 2017. View Article : Google Scholar : PubMed/NCBI
34	Yau C, Esserman L, Moore DH, Waldman F, Sninsky J and Benz CC: A multigene predictor of metastatic outcome in early stage hormone receptor-negative and triple-negative breast cancer. Breast Cancer Res. 12:R852010. View Article : Google Scholar : PubMed/NCBI
35	Ding Y, Li Y, Duan Y, Wang W, Zheng W, Cheng W, Qi Y, Feng J, Chen Z, Yu T, et al: LncRNA MBNL1-AS1 represses proliferation and cancer Stem-Like properties of breast cancer through MBNL1-AS1/ZFP36/CENPA Axis. J Oncol. 2022:99993432022. View Article : Google Scholar : PubMed/NCBI
36	Fang S, Zhao Y and Hu X: LncRNA ADAMTS9-AS1 restrains the aggressive traits of breast carcinoma cells via sponging miR-513a-5p. Cancer Manag Res. 12:10693–10703. 2020. View Article : Google Scholar : PubMed/NCBI
37	Dong X, Yang Y, Xu G, Tian Z, Yang Q, Gong Y and Wu G: The initial expression alterations occurring to transcription factors during the formation of breast cancer: Evidence from bioinformatics. Cancer Med. 11:1371–1395. 2022. View Article : Google Scholar : PubMed/NCBI
38	Calzolari A, Deaglio S, Maldi E, Cassoni P, Malavasi F and Testa U: TfR2 expression in human colon carcinomas. Blood Cells Mol Dis. 43:243–249. 2009. View Article : Google Scholar : PubMed/NCBI
39	Calzolari A, Larocca LM, Deaglio S, Finisguerra V, Boe A, Raggi C, Ricci-Vitani L, Pierconti F, Malavasi F, De MariaR, et al: Transferrin receptor 2 is frequently and highly expressed in glioblastomas. Transl Oncol. 3:123–134. 2010. View Article : Google Scholar : PubMed/NCBI
40	Zhao QF, Ji J, Cai Q, Wang C, Shi M, Zhou CF, Zhu ZG and Zhang J: Low expression of transferrin receptor 2 predict poor prognosis in gastric cancer patients. Kaohsiung J Med Sci. 36:1014–1020. 2020. View Article : Google Scholar : PubMed/NCBI
41	Cao Y, Chen C, Tao Y, Lin W and Wang P: Immunotherapy for Triple-Negative Breast Cancer. Pharmaceutics. 13:20032021. View Article : Google Scholar : PubMed/NCBI
42	Xu X, Wang D, Chen W, Li N, Suwinski R, Rossi A, Rosell R, Zhong J and Fan Y: A nomogram model based on peripheral blood lymphocyte subsets to assess the prognosis of non-small cell lung cancer patients treated with immune checkpoint inhibitors. Transl Lung Cancer Res. 10:4511–4525. 2021. View Article : Google Scholar : PubMed/NCBI
43	Adams S, Schmid P, Rugo HS, Winer EP, Loirat D, Awada A, Cescon DW, Iwata H, Campone M, Nanda R, et al: Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: Cohort A of the phase II KEYNOTE-086 study. Ann Oncol. 30:397–404. 2019. View Article : Google Scholar : PubMed/NCBI
44	Hsu SK, Li CY, Lin IL, Syue WJ, Chen YF, Cheng KC, Teng YN, Lin YH, Yen CH and Chiu CC: Inflammation-related pyroptosis, a novel programmed cell death pathway, and its crosstalk with immune therapy in cancer treatment. Theranostics. 11:8813–8835. 2021. View Article : Google Scholar : PubMed/NCBI
45	Wu S, Pan R, Lu J, Wu X, Xie J, Tang H and Li X: Development and verification of a prognostic Ferroptosis-Related gene model in Triple-Negative breast cancer. Front Oncol. 12:8969272022. View Article : Google Scholar : PubMed/NCBI